Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Innolake Biopharm logo — A clinical stage biotech company, aiming to provide innovati...

Innolake Biopharm

A clinical stage biotech company, aiming to provide innovative therapeutics in oncology and autoimmune disease areas.

Founded 2020 China Shanghai, China 5 employees Series A Total: $400.00M Biotechnology, Health and Wellness

General Information

Company Name Innolake Biopharm
Founded Year 2020
Location China Shanghai, China +1
Employees 5
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Social

Get notified when Innolake Biopharm moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Innolake Biopharm

Innolake Biopharm is a clinical stage biotech company based in China, focusing on innovative therapeutics in oncology and autoimmune disease areas. Founded in 2020 by industry veterans Dr. Mingde Xia and Mr. Robert Chen, the company has made significant strides in a short time. With a $40 million Series Pre-A funding backed by WuXi, Zhongbo Juli, and Hangzhou Heda Industry Fund, Innolake emphasizes innovation as the core of its strategy. The company has a top-tier scientific and clinical development team and is committed to developing proprietary technology platforms and R&D capabilities. It has established a robust pipeline with more than ten first-in-class and best-in-class drug candidates, with two entering the clinical stage. Recently, Innolake was recognized as a “Chinese Next Unicorn” enterprise and listed on the ”2021 China Biopharmaceutical Industry Innovation Top100 List”. Innolake's vision to improve the lives of patients globally through its innovative medicines against cancer and autoimmune diseases, coupled with a strong scientific and clinical team and significant backing, positions it as a promising player in the biotech industry.

Taxonomy: biotech company, oncology therapeutics, autoimmune disease therapeutics, clinical stage, innovative medicines, proprietary technology platforms, R&D capabilities, drug candidates, clinical development, Chinese biopharmaceutical industry, unicorns of China, innovation in biopharmaceuticals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 3
Investor Investor
•••• •••• 		05 Jun 2023
Seed Round •••••• 4
Investor Investor Investor
•••• •••• 		01 Jan 2021

Innolake Biopharm Alternatives & Competitors

Innolake Biopharm vs
Asceneuron SA
Asceneuron SA Switzerland

Targeting the root cause of neurodegeneration

Series C
20 employees
Biotechnology, Health Care
Innolake Biopharm vs
Molecular Partners
Molecular Partners Switzerland

Pioneering DARPin Therapeutics for Patients

Post Ipo Equity
174 employees
Biotechnology, Pharmaceutical
Innolake Biopharm vs
Scioto Biosciences, Inc
Scioto Biosciences, Inc United States

Scioto Biosciences is a Clinical stage biotech company dedicated to innovative research and discover...

Series B
7 employees
Biotechnology, Health Care

FAQ About Innolake Biopharm

A clinical stage biotech company, aiming to provide innovative therapeutics in oncology and autoimmune disease areas.
Innolake Biopharm was founded in 2020.
Innolake Biopharm is headquartered in Shanghai, China.
Innolake Biopharm operates in the following industries: Biotechnology, Health and Wellness.
Innolake Biopharm has approximately 5 employees.
Innolake Biopharm has completed 2 funding rounds, raising a total of $400.00M. The latest funding stage is Series A.
Top alternatives and competitors to Innolake Biopharm include Asceneuron SA, Molecular Partners, Scioto Biosciences, Inc, SanReno Therapeutics, Xynomic Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Innolake Biopharm and Asceneuron SA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Innolake Biopharm and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes